SideChannel (SDCH) 10-K 5 Jan 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2014	Dec. 18, 2014
Entity Registrant Name	NATIONAL SCIENTIFIC CORP/AZ
Entity Central Index Key	1022505
Document Type	10-K
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$4,234,374
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Common Stock
Entity Common Stock, Shares Outstanding		283,473,722
Preferred Stock
Entity Common Stock, Shares Outstanding		4,000,000

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2014	Sep. 30, 2013
CURRENT ASSETS:
Cash	$545,650	$8,587
Accounts receivable	1,006	8,338
Assets attributable to discontinued operations	6,887
Total current assets	553,543	16,925
Proprietary technology, net	604,301	817,921
TOTAL ASSETS	1,157,844	834,846
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	649,452	361,994
Liabilities attributable to discontinued operations	18	35,356
Lines of credit	53,612	9,796
Stock payable	7,000
Total current liabilities	710,082	407,146
TOTAL LIABILITIES	710,082	407,146
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding as of September 30, 2014 and 2013	40,000	40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 283,473,722 and 214,624,216 issued and outstanding as of September 30, 2014 and 2013, respectively	2,834,737	2,146,242
Additional paid-in capital	25,828,751	24,783,723
Accumulated deficit	-28,255,726	-26,542,265
Total stockholders' equity	447,762	427,700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$1,157,844	$834,846

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Authorized	4,000,000	4,000,000
Preferred Stock, Shares Issued	4,000,000	4,000,000
Preferred Stock, Shares Outstandng	4,000,000	4,000,000
Common Stock, Par Value	$0.01	$0.01
Common Stock, Shares Authorized	650,000,000	650,000,000
Common Stock, Shares Issued	283,473,722	214,624,216
Common Stock, Shares Outstanding	283,473,722	214,624,216

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
REVENUE	$1,339,155	$516,868
COST OF REVENUES	240,270	243,470
GROSS PROFIT	1,098,885	273,398
OPERATING EXPENSES:
General and administrative	2,810,757	714,266
Research and development	37,729	208,895
Impairment of assets		6,000
Total operating expenses	2,848,486	929,161
OPERATING LOSS	-1,749,601	-655,763
OTHER (INCOME) AND EXPENSES
Interest expense	2,430	392
Gain on the disposal of assets		-1,353
Total other (income) expenses	2,430	-961
LOSS FROM CONTINUING OPERATIONS	-1,752,031	-654,802
INCOME FROM DISCONTINUED OPERATIONS	38,570	23,628
NET LOSS	($1,713,461)	($631,174)
NET LOSS PER COMMON SHARE - Basic and diluted:
Continuing operations	($0.01)	$0
Discontinued operations	$0	$0
Total	($0.01)	$0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic and diluted	247,477,420	212,798,744

Shareholders_Equity

Shareholders Equity (USD $)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning, Value at Sep. 30, 2012	$40,000	$2,119,912	$24,552,924	($25,911,091)	$801,745
Beginning, Shares at Sep. 30, 2012	4,000,000	211,991,212
Common stock issued for asset acquisition, Shares		300,000
Common stock issued for asset acquisition, value		3,000	3,000		6,000
Common stock issued for intangible asset acquisition, Shares		500,004
Common stock issued for intangible asset acquisition, Value		5,000	10,800		15,800
Common stock issued to officers for services, Value					36,629
Common stock issued for the purchase of billing software, Shares		450,000			450,000
Common stock issued for the purchase of billing software, Value		4,500	9,063		13,563
Common stock issued for consulting services, Shares		1,165,500			1,165,600
Common stock issued for consulting services, Value		11,655	24,974		36,629
Common stock issued for cash, Shares		217,500			217,500
Common stock issued for cash, Value		2,175	140,825		143,000
Write-off of related party debt			42,137		42,137
Net loss				-631,174	-631,174
Ending, Value at Sep. 30, 2013	40,000	2,146,242	24,783,723	-26,542,265	427,700
Ending, Shares at Sep. 30, 2013	4,000,000	214,624,216
Common stock issued for asset acquisition, Shares		200,000
Common stock issued for asset acquisition, value		2,000	4,000		6,000
Common stock issued to officers for services, Shares		31,750,000
Common stock issued to officers for services, Value		317,500	349,250		666,750
Common stock issued for the purchase of billing software, Shares		220,000			220,000
Common stock issued for the purchase of billing software, Value		2,200	3,500		5,700
Common stock issued for consulting services, Shares		36,492,506			68,242,506
Common stock issued for consulting services, Value		364,925	593,444		958,369
Common stock issued for cash, Shares		187,000			187,000
Common stock issued for cash, Value		1,870	35,130		37,000
Write-off of related party debt			59,704		59,704
Net loss				-1,713,461	-1,713,461
Ending, Value at Sep. 30, 2014	$40,000	$2,834,737	$25,828,751	($28,255,726)	$447,762
Ending, Shares at Sep. 30, 2014	4,000,000	283,473,722

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows [Abstract]
Net loss	($1,713,461)	($631,174)
Income from discontinued operations	-38,570	-23,628
Loss from continuing operations	-1,752,031	-654,802
Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities:
Depreciation and amortization	244,620	243,470
Impairment of assets		6,000
Stock issued for compensation	1,625,119	36,629
Stock issued with licensing agreements	5,700	13,563
Changes in operating assets and liabilities:
Accounts receivable	7,332	-3,450
Accounts payable and accrued liabilities	343,507	221,879
Stock payable	7,000
Net cash provided by (used in) operating activities	481,247	-136,711
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible asset	-25,000	-11,500
Net cash used in investing activities	-25,000	-11,500
CASH FLOWS FROM FINANCING ACTIVITIES:
Advances from officer	8,299	5,409
Repayment of advances from officer	-8,299	-31,000
Proceeds from line of credit	103,529	11,144
Repayment of line of credit	-59,713	-23,111
Common stock issued for cash	37,000	143,000
Net cash provided by financing activities	80,816	105,442
INCREASE (DECREASE) IN CASH	537,063	-42,769
CASH, BEGINNING OF YEAR	8,587	51,356
CASH, END OF YEAR	545,650	8,587
CASH PAID FOR:
Interest	2,726
Taxes
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Accrual of software acquisition costs		11,500
Write-off of debt - related parties	59,704	42,137
Common stock issued for investment in Doctors Network of America		6,000
Common stock issued for purchase of software	$6,000	$15,800

1_DESCRIPTION_OF_BUSINESS

1. DESCRIPTION OF BUSINESS	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
1. DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS
	Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.
	In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.
	During the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.
	On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. Since 2012, the Company has tested the software application and created a commercial product for distribution of its encryption technology. The Company is presently developing more applications for consumer usage in the future.
	On September 1, 2014, the Company purchased Evolve Software for $25,000, which is a front office interface that complements our back office medical billing software. The Company has bridged the software to provide a more user friendly medical billing package for our customers.

2_BASIS_OF_PRESENTATION

2. BASIS OF PRESENTATION	12 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2. BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION
	Segment reporting change
	With the placement into service of the Company’s encryption technology, the Company began a segment reporting structure to match the new operating structure and how the Company’s management views the business and allocates resources, beginning in the year ended September 30, 2014. Reclassifications of prior period financial information have been made to conform to the current period presentation. This change does not impact previously reported consolidated financial statements of the Company. See Note 12 for additional information on our segment reporting change.

3_GOING_CONCERN_ISSUES

3. GOING CONCERN ISSUES	12 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
3. GOING CONCERN ISSUES	NOTE 3 - GOING CONCERN ISSUES
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates continuation of the Company as a going concern. However, the Company has incurred losses from operations, has an accumulated deficit at September 30, 2014 of $28,255,726 and needs additional cash to maintain its operations.
	These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

4_SUMMARY_OF_SIGNIFICANT_ACCOU

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and the valuation of its common stock.
	In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2014 and 2013, cash and cash equivalents include cash on hand and cash in the bank. The Company maintains its cash in accounts held by large, globally recognized banks which, at times, may exceed federally insured limits as guaranteed by the Federal Deposit Insurance Corporation (FDIC). The FDIC insures these deposits up to $250,000. At September 30, 2014, approximately $294,927 of the Company’s cash balance was uninsured. The Company has not experienced any losses in such accounts.
	Long-Lived Assets
	Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.
	Fair Value of Financial Instruments
	The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
	Fair value is defined as an exit price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used, based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
	The three-level hierarchy for fair value measurements is defined as follows:
	•	Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
	•	Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
	•	Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement
	The following table summarizes fair value measurements by level at September 30, 2014 and 2013 for assets measured at fair value on a recurring basis:
		Level 1		Level 2		Level 3		Total
	At September 30, 2014
	Software development, net of amortization	$	—	$	—	$	604,301	$	604,301
	Total Proprietary Technology	$	—	$	—	$	604,301	$	604,301
	At September 30, 2013
	Software development, net of amortization	$	—	$	—	$	817,921	$	817,921
	Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
	Accounts Receivable and Allowance for Uncollectible Accounts
	Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.
	During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in DNA (“Doctors Network of America”), subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) which was completed during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.
	Income Taxes
	The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.
	The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. The Company did not record any liabilities for uncertain tax positions for the years ended September 30, 2014 or 2013.
	Revenue Recognition
	Medical Licensing Agreement
	License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”
	VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
	Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter the software is purchased and installed, the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.
	Transaction revenue is generated from the following services and recognized when a transaction occurs:
	·	Electronic Remittance Advice $0.35 Electronic remittance transaction fee;
	·	Paper Claims $1.00 Paper claim fee;
	·	Carrier Direct $0.16 Carrier direct fee;
	·	Fast Forward $0.35 Fast forward transaction fee; and,
	·	Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient
	The Company had not received any transaction revenues in the years ended September 30, 2014 or 2013.
	CipherLoc Licensing Agreement
	License revenue also consists of revenue earned under a CipherLoc License Agreement. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”
	VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
	Cost of License and Subscriptions Revenue
	Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the years ended September 30, 2014 and 2013.
	Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the years ended September 30, 2014 and 2013.
	The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of five years.
	Deferred Revenue
	Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc.
	The Company has deferred revenue of $0 as of September 30, 2014 and 2013.
	Sales Commissions
	The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically accrued on the date of sale and paid in the month following execution of the customer contracts. The Company paid commissions of $37,000 and $62,060 for the years ended September 30, 2014 and 2013, respectively.
	Research and Development and Software Development Costs
	Capitalization of certain software development costs are recorded after the determination of technological feasibility. Based on our product development process, technological feasibility is determined upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2014 and 2013 were $37,729 and $208,895, respectively.
	Share-Based Compensation
	The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no options or warrants issued by the Company during the years ended September 30, 2014 and 2013.
	Basic and Diluted Net Loss per Common Share
	Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2014 and 2013, the Company had 4,000,000 shares of preferred stock outstanding which are convertible into 600,000,000 shares of common stock.
	Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.
	Concentrations of Risk
All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.
The revenues for the year ended September 30, 2014 were generated from one transaction in June of 2014 of $1,125,000 which represents 84% of our total revenues.
Subsequent Events
The Company has evaluated all transactions occurring from the end of its fiscal year, September 30, 2014, through the date of issuance of the financial statements for subsequent event disclosure consideration.
Recent Accounting Pronouncements
No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

5_SOFTWARE

5. SOFTWARE	12 Months Ended
	Sep. 30, 2014
Research and Development [Abstract]
5. SOFTWARE	NOTE 5 – SOFTWARE
	The following is a detail of software at September 30, 2014 and 2013:
		2014			2013
	Source Code License	$	2,500		$	2,500
	Software License		1,200,106			1,200,106
	EMR Certification		23,000			23,000
	Encryption Software Code		15,800			15,800
	Evolve Software Code		25,000			—
	Compose Rose Code		6,000			—
	Acquisition of Doctor’s Network of America		10,000			10,000
	Total intangible assets		1,282,406			1,251,406
	Accumulated amortization of intangible assets (charged to cost of sales)		(668,105	)		(423,485	)
	Accumulated impairment of assets		(10,000	)		(10,000	)
	Total proprietary technology, net	$	604,301		$	817,921
	The Company’s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $244,620 and $243,470 for the years ended September 30, 2014 and 2013, respectively. The Company recognized a $10,000 impairment of software acquired from Doctors Network of America (“DNA”) operating in Flowood, Mississippi during the years ended September 30, 2014 and 2013. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.
	Source Code License
	In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.
	Encryption Software Code
	On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software and algorithms licensed and sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names and world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.
	Doctors Network of America
	On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.
	Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The amounts billed for transaction fees were written off in the year ended September 30, 2013 as uncollectible. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000.

6_DISCONTINUED_OPERATIONS

6. DISCONTINUED OPERATIONS	12 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]
6. DISCONTINUED OPERATIONS	NOTE 6 - DISCONTINUED OPERATIONS
	GPS Operational Device Business
	The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.
	Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.
	DNA
	On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.
	Details of the classifications for net assets, liabilities and operations are shown below.
		September 30,		September 30,
		2014		2013
	Net liabilities of discontinued operations:
	Accounts payable	$	18	$	35,356
	Net liabilities of discontinued operations	$	18	$	35,356
		Year ended
		September 30,
		2014		2013
	Discontinued operations:
	Revenues	$	207,980	$	431,400
	Cost of sales		—		—
	Operating expenses		169,410		(245,287	)
	Bad debt		—		(221,469	)
	Gain from write-off of debt		—		58,984
	Income from discontinued operations	$	38,570	$	23,628

7_LINES_OF_CREDIT

7. LINES OF CREDIT	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
7. LINES OF CREDIT	NOTE 7 – LINES OF CREDIT
	In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 5.00% interest rate per annum, which renews annually. As of September 30, 2014, the Company had borrowed $53,612 against the line of credit.
	The Company has a revolving line of credit with Chase Bank with a balance as of September 30, 2014 in the amount of $0 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.
	Interest expense for these lines of credit was $2,430 from $392 for the years ended September 30, 2014 and 2013, respectively.

8_DEBT_MITIGATION_PROGRAM

8. DEBT MITIGATION PROGRAM	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
8. DEBT MITIGATION PROGRAM	NOTE 8 – DEBT MITIGATION PROGRAM
	The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during year ended September 30, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $42,137 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.
	The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.
		30-Sep-14		30-Sep-13
	Debt Mitigation Program - Accounts payable and accrued expenses	$	59,704	$	101,121
	Gain on write-off of debt		—		58,984
	Additional paid-in capital (1)	$	59,704	$	42,137
	-1	All amounts that were owed to related parties in prior years were recorded to paid-in capital.

9_COMMITMENTS_AND_CONTINGENCIE

9. COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
9. COMMITMENTS AND CONTINGENCIES	NOTE 9– COMMITMENTS AND CONTINGENCIES
	The Company entered into an agreement to purchase the assets of DNA in June 2012 and, after due diligence by both parties, the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.
	The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will terminate and shareholders that received anti-reverse split stock will be subject to all future stock splits. The Company has issued 90,029,843 anti-reverse split shares and these holders will hold the same number of shares after the reverse split has been completed. The company applied for a 100:1 reverse stock split on September 6, 2014. Had the Company completed the reverse stock split by September 30, 2014, the price of the Company stock would have been $2.49, and 89,129,545 additional shares would have been issued at a total of $221,932,567.
	As discussed in Note 8, the Company has written off $59,704 and $101,121 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the years ended September 30, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.
	In June 2014, the Company entered into an investor relations agreement and market awareness consulting agreement with BCMG Entertainment, Inc. (“BCMG”) for $450,000. The Company has paid BCMG $200,000 as of September 30, 2014. The Company will continue to pays $25,000 per month based on performance until the contract is satisfied. The Company has terminated this contract in full satisfaction of the contract on October 8, 2014.
	Employment Contracts
	The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The Employment Agreement provides for:
	i.	A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
	ii.	A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2014 and 2013):
	a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
	b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or
	iii.	The issuance of shares equal to the greater of 1% of the then issued and outstanding shares of the Company annually, or 3,000,000 shares. The Company issued these shares in March 2014.
	iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
	v.	An automobile allowance of $1,500 per month.
	vi.	A medical insurance allowance of $1,500 per month.
	vii.	In the event the executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.
	The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:
	i.	A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
	ii.	A cash bonus of 25% of her annual base salary each year if the Company reaches the following milestones (none of which were attained in 2014 and 2013):
	a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
	b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or
	iii.	The issuance of shares equal to the greater of 1% of the then issued and outstanding shares of the Company annually, or 3,000,000 shares. The Company issued these shares in March 2014.
	iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
	v.	An automobile allowance of $1,000 per month.
	vi.	A medical insurance allowance of $1,500 per month.
	vii.	In the event the executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.
	There are additional shares due to the officers of the Company and the Board has not granted these shares nor determined the amounts due at this time.

10_RELATED_PARTY_TRANSACTIONS

10. RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
10. RELATED PARTY TRANSACTIONS	NOTE 10– RELATED PARTY TRANSACTIONS
	The Company repaid $8,299 and $25,591 of the advances from the Company’s CEO in the years ended September 30, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of September 30, 2014 and 2013, there were no amounts owed to the CEO for advances.

11_EQUITY

11. EQUITY	12 Months Ended
	Sep. 30, 2014
Equity [Abstract]
11. EQUITY	NOTE 11 - EQUITY
	As of September 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01 per share.
	Fiscal Year Ended September 30, 2014
	The Company received $7,000 for the issuance of 50,000 shares of common stock recorded as stock payable and as of September 30, 2014 the common stock has not been issued by the Company.
	Stock Issued for Cash
	During the year ended September 30, 2014, the Company issued 187,000 shares of common stock for $37,000 in net cash proceeds as follows:
	Date		Number of Shares		Proceeds
		21-Oct-13		25,000	$	5,000
		12-Jan-14		10,000		10,000
		3-Sep-14		152,000		22,000
		Total		187,000	$	37,000
	Stock Issued in Connection with Software Licensing and Subscription Agreements
	During the year ended September 30, 2014, the Company issued 220,000 shares of common stock valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized.
	Date		Number of Shares		Fair Value
		4-Dec-13		120,000	$	3,600
		21-Feb-14		100,000		2,100
		Total		220,000	$	5,700
	Stock Issued for Asset Acquisition
	In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.
	In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to the shareholders.
	Stock Issued for Services
	During the year ended September 30, 2014, the Company issued 68,242,506 shares of common stock as compensation. The fair values of the shares were a total of $1,625,119 and were recorded at the market price on the date of grant. The issuances of stock were as follows:
	Date		Number of Shares			Fair Value	Description of Services
		5-Mar-14		31,750,000	$	666,750	Compensation to officers
		3-Apr-14		5,000		116	Compensation for legal services
		21-Apr-14		1,392,506		34,227	Compensation for CipherLoc consultants
		22-Apr-14		7,000,000		138,600	Marketing agreement with Hemp, Inc.
		3-May-14		5,000		115	Compensation for legal services
		5-May-14		50,000		1,150	Compensation for marketing services
		6-May-14		25,000,000		605,000	Compensation to a sales consultant
		3-Jun-14		5,000		111	Compensation for legal services
		7-Jul-14		35,000		1,750	Compensation for CipherLoc consultants
		3-Sep-14		3,000,000		177,300	Compensation for marketing services
		Total		68,242,506	$	1,625,119
	In June 2014, the Company entered into a consulting agreement with Gawk, Inc. This agreement required the issuance of 3,000,000 common shares and Gawk has agreed to assist the Company in seeking additional purchasers of CipherLoc Encryption Technology within the entertainment industry.
	Fiscal Year Ended September 30, 2013
	Stock Issued for Cash
	During the year ended September 30, 2013, the Company issued 217,500 shares of common stock for $143,000 in net proceeds as follows:
	Date		Number of Shares		Proceeds
		14-Oct-12		20,000	$	20,000
		14-Oct-12		15,000		3,000
		14-Oct-12		18,750		2,500
		14-Oct-12		18,750		2,500
		6-Dec-12		15,000		3,000
		12-Mar-13		20,000		20,000
		12-Mar-13		20,000		20,000
		March 31, 2013		50,000		50,000
		17-Apr-13		20,000		20,000
		26-Aug-13		20,000		2,000
		Total		217,500	$	143,000
	Stock Issued in Connection with Software Licensing and Subscription Agreements
	During the year ended September 30, 2013, the Company issued 450,000 shares of common stock valued at $13,563, based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the software licensing and subscription agreements.
	The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2013.
	Date		Number of Shares		Fair Value
		14-Oct-12		50,000	$	1,300
		6-Dec-12		100,000		2,800
		12-Mar-13		50,000		1,750
		21-Mar-13		50,000		1,750
		21-Mar-13		50,000		1,750
		17-Apr-13		25,000		838
		17-Apr-13		50,000		1,675
		26-Jun-13		25,000		450
		30-Sep-13		50,000		1,250
		Total		450,000	$	13,563
Stock Issued for Services
During the year ended September 30, 2013, the Company issued 1,165,500 shares of common stock as compensation. The fair values of the shares were a total of $36,629 and were recorded at the market price on the date of grant. The issuances of stock were as follows:
Date		Number of Shares		Fair Value		Description of Services
	14-Oct-12		10,000		260	Commission
	6-Dec-12		100,000		2,800	Software Agreement
	12-Mar-13		50,000		1,750	Consulting
	21-Mar-13		167,000		5,845	Compensation
	21-Mar-13		500,000		17,500	Compensation
	17-Apr-13		78,500		2,630	Compensation
	1-May-13		20,000		522	Programming
	10-May-13		20,000		522	Programming
	26-Aug-13		100,000		1,800	Software Sales
	30-Sep-13		60,000		1,500	Programming
	30-Sep-13		60,000		1,500	Programming
	Total		1,165,500	$	36,629
Stock Issued for Intangible Asset and Asset Acquisition
On April 17, 2013, the Company issued 300,000 shares of common stock valued at $6,000, based on the market price on the date of grant, to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company.
During year ended September 30, 2013, the Company issued 500,004 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $15,800 based on the market price on the dates of grant.
Preferred Stock
The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value. The Company established and designated the rights and preferences of a Series A Preferred Stock, and reserved 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of common stock. All 4,000,000 shares of preferred stock were issued to our CEO and CFO on April 11, 2011.

12_SEGMENT_INFORMATION

12. SEGMENT INFORMATION	12 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]
12. SEGMENT INFORMATION	NOTE 12 – SEGMENT INFORMATION
	Cloud Medical Doctors Software Corporation has two reporting segments and corporate overhead:
	•	Cloud-MD – the Company sells medical billing software to doctors. Prior to 2014, all of the Company’s business activities were derived from this segment.
	•	CipherLoc – the Company licenses encryption technology software that can be used by larger corporations to protect their data through our polymorphic technology.
	•	Corporate Overhead – the Company’s activities that are used to finance the current operations and expansion of its segments.
	The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before income taxes, not including nonrecurring gains and losses and foreign exchange gains and losses. The reportable segments are strategic business units that offer different technology and marketing strategies. Most of the businesses were developed internally and management remains the same. To date, the Company’s operations are principally in the United States.
	Consolidated revenues from external customers, operating loss, and identifiable assets were as follows:
		Year ended September 30,
		2014			2013
	Revenues:
	Cloud-MD	$	214,155		$	516,868
	CipherLoc		1,125,000			—
	Total revenues	$	1,339,155		$	516,868
	Operating Income (loss):
	Cloud-MD	$	63,905		$	58,503
	CipherLoc		1,094,317			—
	Corporate		(2,780,013	)		(714,266	)
	Operating Loss	$	(1,749,601	)	$	(655,763	)
		September 30,     2014			September 30,
					2013
	Identifiable assets:
	Cloud-MD	$	583,870		$	810,459
	CipherLoc		21,437			15,800
	Corporate		552,537			8,587
	Total identifiable assets	$	1,157,844		$	834,846

13_INCOME_TAXES

13. INCOME TAXES	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
13. INCOME TAXES	NOTE 13 - INCOME TAXES
	Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The Company has a net operating loss carryforward of approximately $25.9 million available to offset future taxable income through 2014. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.
	For the years ended September 30, 2014 and 2013, the difference between the amounts of income tax expense or benefit that would result from applying the statutory rates to pretax income to the reported income tax expense of $0 is the result of the net operating loss carryforward and the related valuation allowance.
	The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.

4_SUMMARY_OF_SIGNIFICANT_ACCOU1

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and the valuation of its common stock.
	In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2014 and 2013, cash and cash equivalents include cash on hand and cash in the bank. The Company maintains its cash in accounts held by large, globally recognized banks which, at times, may exceed federally insured limits as guaranteed by the Federal Deposit Insurance Corporation (FDIC). The FDIC insures these deposits up to $250,000. At September 30, 2014, approximately $294,927 of the Company’s cash balance was uninsured. The Company has not experienced any losses in such accounts.
Long-Lived Assets	Long-Lived Assets
	Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
	Fair value is defined as an exit price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used, based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
	The three-level hierarchy for fair value measurements is defined as follows:
	•	Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
	•	Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
	•	Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement
	The following table summarizes fair value measurements by level at September 30, 2014 and 2013 for assets measured at fair value on a recurring basis:
		Level 1		Level 2		Level 3		Total
	At September 30, 2014
	Software development, net of amortization	$	—	$	—	$	604,301	$	604,301
	Total Proprietary Technology	$	—	$	—	$	604,301	$	604,301
	At September 30, 2013
	Software development, net of amortization	$	—	$	—	$	817,921	$	817,921
	Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts
	Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.
	During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in DNA (“Doctors Network of America”), subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) which was completed during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.
Income Taxes	Income Taxes
	The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.
	The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. The Company did not record any liabilities for uncertain tax positions for the years ended September 30, 2014 or 2013.
Revenue Recognition	Revenue Recognition
	Medical Licensing Agreement
	License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”
	VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
	Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter the software is purchased and installed, the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.
	Transaction revenue is generated from the following services and recognized when a transaction occurs:
	·	Electronic Remittance Advice $0.35 Electronic remittance transaction fee;
	·	Paper Claims $1.00 Paper claim fee;
	·	Carrier Direct $0.16 Carrier direct fee;
	·	Fast Forward $0.35 Fast forward transaction fee; and,
	·	Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient
	The Company had not received any transaction revenues in the years ended September 30, 2014 or 2013.
	CipherLoc Licensing Agreement
	License revenue also consists of revenue earned under a CipherLoc License Agreement. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”
	VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
Deferred Revenue	Deferred Revenue
	Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc.
	The Company has deferred revenue of $0 as of September 30, 2014 and 2013.
Sales Commissions	Sales Commissions
	The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically accrued on the date of sale and paid in the month following execution of the customer contracts. The Company paid commissions of $37,000 and $62,060 for the years ended September 30, 2014 and 2013, respectively.
Research and Development and Software Development Costs	Research and Development and Software Development Costs
	Capitalization of certain software development costs are recorded after the determination of technological feasibility. Based on our product development process, technological feasibility is determined upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2014 and 2013 were $37,729 and $208,895, respectively.
Share-Based Compensation	Share-Based Compensation
	The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no options or warrants issued by the Company during the years ended September 30, 2014 and 2013.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share
	Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2014 and 2013, the Company had 4,000,000 shares of preferred stock outstanding which are convertible into 600,000,000 shares of common stock.
	Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.
Concentrations of Risk	Concentrations of Risk
	All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.
	The revenues for the year ended September 30, 2014 were generated from one transaction in June of 2014 of $1,125,000 which represents 84% of our total revenues.
Subsequent Events	Subsequent Events
	The Company has evaluated all transactions occurring from the end of its fiscal year, September 30, 2014, through the date of issuance of the financial statements for subsequent event disclosure consideration.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

4_SUMMARY_OF_SIGNIFICANT_ACCOU2

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Fair Value of Financial Instruments		Level 1		Level 2		Level 3		Total
	At September 30, 2014
	Software development, net of amortization	$	—	$	—	$	604,301	$	604,301
	Total Proprietary Technology	$	—	$	—	$	604,301	$	604,301
	At September 30, 2013
	Software development, net of amortization	$	—	$	—	$	817,921	$	817,921
	Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921

5_SOFTWARE_Tables

5. SOFTWARE (Tables)	12 Months Ended
	Sep. 30, 2014
Research and Development [Abstract]
Software		2014			2013
	Source Code License	$	2,500		$	2,500
	Software License		1,200,106			1,200,106
	EMR Certification		23,000			23,000
	Encryption Software Code		15,800			15,800
	Evolve Software Code		25,000			—
	Compose Rose Code		6,000			—
	Acquisition of Doctor’s Network of America		10,000			10,000
	Total intangible assets		1,282,406			1,251,406
	Accumulated amortization of intangible assets (charged to cost of sales)		(668,105	)		(423,485	)
	Accumulated impairment of assets		(10,000	)		(10,000	)
	Total proprietary technology, net	$	604,301		$	817,921

6_DISCONTINUED_OPERATIONS_Tabl

6. DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations		September 30,		September 30,
		2014		2013
	Net liabilities of discontinued operations:
	Accounts payable	$	18	$	35,356
	Net liabilities of discontinued operations	$	18	$	35,356
		Year ended
		September 30,
		2014		2013
	Discontinued operations:
	Revenues	$	207,980	$	431,400
	Cost of sales		—		—
	Operating expenses		169,410		(245,287	)
	Bad debt		—		(221,469	)
	Gain from write-off of debt		—		58,984
	Income from discontinued operations	$	38,570	$	23,628

8_DEBT_MITIGATION_PROGRAM_Tabl

8. DEBT MITIGATION PROGRAM (Tables)	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Debt Mitigation Program		30-Sep-14		30-Sep-13
	Debt Mitigation Program - Accounts payable and accrued expenses	$	59,704	$	101,121
	Gain on write-off of debt		—		58,984
	Additional paid-in capital (1)	$	59,704	$	42,137

12_SEGMENT_INFORMATION_Tables

12. SEGMENT INFORMATION (Tables)	12 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]
Segment Information		Year ended September 30,
		2014			2013
	Revenues:
	Cloud-MD	$	214,155		$	516,868
	CipherLoc		1,125,000			—
	Total revenues	$	1,339,155		$	516,868
	Operating Income (loss):
	Cloud-MD	$	63,905		$	58,503
	CipherLoc		1,094,317			—
	Corporate		(2,780,013	)		(714,266	)
	Operating Loss	$	(1,749,601	)	$	655,763
		September 30,     2014			September 30,
					2013
	Identifiable assets:
	Cloud-MD	$	583,870		$	810,459
	CipherLoc		21,437			15,800
	Corporate		552,537			8,587
	Total identifiable assets	$	1,157,844		$	834,846

1_DESCRIPTION_OF_BUSINESS_Deta

1. DESCRIPTION OF BUSINESS (Details Narrative) (Evolve Software [Member], USD $)	12 Months Ended
	Sep. 30, 2014
Evolve Software [Member]
Software Purchase Price	$25,000

3_GOING_CONCERN_ISSUES_Details

3. GOING CONCERN ISSUES (Details Narrative) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	($28,255,726)	($26,542,265)

4_SUMMARY_OF_SIGNIFICANT_ACCOU3

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Software	$604,301	$817,921
Total Software	604,301	817,921
Level 1
Software
Total Software
Level 2
Software
Total Software
Level 3
Software	604,301	817,921
Total Software	$604,301	$817,921

4_SUMMARY_OF_SIGNIFICANT_ACCOU4

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]
FDIC Insured Cash	$250,000
Subscription Revenue, Year One	1,200
Subscription Revenue, Year Two	1,500
Subscription Revenue, Year Three	1,800
Subscription Revenue, Year Four	2,400
Deferred Revenue	0
Sales Commissions	37,000	62,060
Research and Development Costs	37,729	208,895
Cash held in excess of FDIC Insured Amount	294,927
Accounts Recievable, Written Off	200,000
Concentration of Risk, Revenues	$1,125,000
Concentration of Risk, Percentage of Revenues	84.00%
Preferred Stock, Shares Outstanding	4,000,000	4,000,000
Preferred Stock, Shares Convertible	600,000,000

5_SOFTWARE_Software_Details

5. SOFTWARE - Software (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Intangible assets	$1,282,406	$1,251,406
Accumulated amortization of intangible assets	-668,105	-423,485
Accumulated impairment of assets	-10,000	-10,000
Intangible assets, Net	604,301	817,921
Source Code License [Member]
Intangible assets	2,500	2,500
Software License [Member]
Intangible assets	1,200,106	1,200,106
EMR Certification [Member]
Intangible assets	23,000	23,000
Encryption Software Code [Member]
Intangible assets	15,800	15,800
Evolve Software Code [Member]
Intangible assets	25,000
Compose Rose Code [Member]
Intangible assets	6,000
Doctors Network of America [Member]
Intangible assets	$10,000	$10,000

5_SOFTWARE_Details_Narrative

5. SOFTWARE (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 16, 2013	Sep. 30, 2012
Amortization Expense	$244,620	$243,470
Stock issued Purchase of Asset, Shares	200,000	300,000
Stock Issued Purchase of Asset, Value	6,000	6,000
Doctors Network of America [Member]
Software Impairment	10,000	10,000
Stock Issued, Acquisition, Shares		500,000
Shares Issued			300,000	200,000
Shares Issued, Value			6,000	4,000
Amount Due from Acquisition				200,000
Source Code License [Member]
Stock issued Purchase of Asset, Shares	200,000
Stock Issued Purchase of Asset, Value	6,000
Encryption Software Code [Member]
Stock issued Purchase of Asset, Shares	500,004
Stock Issued Purchase of Asset, Value	$15,800

6_DISCONTINUED_OPERATIONS_Disc

6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Net liabilities of discontinued operations	$18	$35,356
Revenues	1,339,155	516,868
Cost of sales	240,270	243,470
Operating expenses	2,848,486	929,161
Gain from write-off of debt		58,984
Discontinued Operations [Member]
Accounts payable	18	35,356
Net liabilities of discontinued operations	18	35,356
Revenues	207,980	431,400
Cost of sales
Operating expenses	169,410	-245,287
Bad Debt		-221,469
Gain from write-off of debt		58,984
(Loss) income from discontinued operations	$38,570	$23,628

7_LINES_OF_CREDIT_Details_Narr

7. LINES OF CREDIT (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Interest Expense	$2,430	$392
Mutual of Omaha
Revolving Line of Credit, Borrowing Capacity	65,000
Line of Credit Interest Rate	5.00%
Line of Credit, Amount Outstanding	53,612
Chase Bank
Revolving Line of Credit, Borrowing Capacity	50,000
Line of Credit Interest Rate	4.25%
Line of Credit, Amount Outstanding	$0

8_DEBT_MITIGATION_PROGRAM_Debt

8. DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) (USD $)	12 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Debt Disclosure [Abstract]
Debt Mitigation Program - Accounts payable and accrued expenses	$59,704		$101,121
Gain on write-off of debt			58,984
Additional paid-in capital	$59,704	[1]	$42,137	[1]
[1]	1) All amounts that were owed to related parties in prior years were recorded to paid-in capital.

8_DEBT_MITIGATION_PROGRAM_Deta

8. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Debt Disclosure [Abstract]
Gain on the Write-Off of Liabilities	$0		$58,984
Additional Paid-In Capital for Related Party Liabilities	$59,704	[1]	$42,137	[1]
[1]	1) All amounts that were owed to related parties in prior years were recorded to paid-in capital.

9_COMMITMENTS_AND_CONTINGENCIE1

9. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Payable Write Offs	$59,704	$101,121
Legal Contingencies	200,000
Anti-Reverse Split Shares Issued	90,029,843
Professional Services Fees, Aggregate	450,000
Professional Services Fees, Paid	200,000
Professional Services Fees, Periodic Payments	$25,000

10_RELATED_PARTY_TRANSACTIONS_

10. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Related Party Transactions [Abstract]
Repayment of Advances from Related Parties	($8,299)	($31,000)

11_EQUITY_Details_Narrative

11. EQUITY (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Common Stock, Shares Authorized	650,000,000	650,000,000
Preferred Stock Shares Authorized	4,000,000	4,000,000
Common Stock, Par Value	$0.01	$0.01
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Issued	4,000,000	4,000,000
Preferred Stock Shares Outstanding	4,000,000	4,000,000
Preferred Stock, Voting Rights		150
Preferred Stock, Trading Price of the Common Stock		$0.01
Stock Payable, Value	$7,000
Stock Payable, Shares	50,000
Stock Issued for Cash, Shares	187,000	217,500
Stock Issued for Cash, Value	37,000	143,000
Stock Issued for Software Licensing and Subscription Agreements, Shares	220,000	450,000
Stock Issued for Software Licensing and Subscription Agreements, Value	5,700	13,563
Stock Issued for Assets Acquisition, Shares	200,000	300,000
Stock Issued for Assets Acquisition, Value	6,000	6,000
Stock Issued for Replacement, Shares	180,000
Stock Issued for Services, Shares	68,242,506	1,165,600
Stock Issued for Services, Value	958,369	36,629
Cipher Smith Software [Member]
Stock Issued for Assets Acquisition, Shares		500,004
Stock Issued for Assets Acquisition, Value		$15,800
Gawk Inc.
Stock Issued for Services, Shares	3,000,000
Antree Systems Limited
Stock Issued for Replacement, Shares	160,000
Kimberly Ilicerl
Stock Issued for Replacement, Shares	20,000

12_SEGMENT_INFORMATION_Segment

12. SEGMENT INFORMATION - Segment Information (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Revenues:	$1,339,155	$516,868
Operating expenses:	-1,749,601	-655,763
Identifiable assets:	1,157,844	834,846
Cloud MD [Member]
Revenues:	214,155	516,868
Operating expenses:	63,905	58,503
Identifiable assets:	583,870	810,459
CipherLoc [Member]
Revenues:	1,125,000
Operating expenses:	1,094,317
Identifiable assets:	21,437	15,800
Corporate [Member]
Operating expenses:	-2,780,013	-714,266
Identifiable assets:	$552,537	$8,587

13_INCOME_TAXES_Details_Narrat

13. INCOME TAXES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Net Operating Loss Carryforward	$25,900,000
Income Tax Expense